In a report released today, Charles Zhu from LifeSci Capital maintained a Buy rating on Merus (MRUS – Research Report), with a price ...
Merus’ zenocutuzumab is nearing FDA approval, and petosemtamab shows promise. Learn why MRUS stock could rise as the company ...
Despite the PDUFA date being extended by three months for Merus’ zenocutuzumab, Truist Securities analyst Asthika ...
Mirae Asset Global Investments Co. Ltd. increased its position in shares of Merus (NASDAQ:MRUS – Free Report) by 24.7% in the 3rd quarter, Holdings Channel.com reports. The fund owned 2,467 shares of ...
Third Quarter 2024 Results Key Financial Results Revenue: US$11.8m (up 6.7% from 3Q 2023).
The FDA is set to decide on four promising therapies in the next two weeks, including a CAR T for acute lymphoblastic ...
TipRanks on MSN5d
Merus reports Q3 EPS ($1.46), consensus (88c)Reports Q3 revenue $11.8M, consensus $7.83M. “I’m encouraged by our continued operational effectiveness, with phase 3 trials accelerating for ...
Oct. 31, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies ...
This update in the health sector highlights major developments including DiaSorin's significant profit growth, GSK's RSV ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback